Compare ARK Genomic Revolution ETF (ARKG) vs Canadian National Railway Co. (CNI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Canadian National Railway Co. — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Canadian National Railway Co. trades at $124.96 (market cap $75.28B). The key difference: Canadian National Railway Co. pays a 2.07% dividend while ARK Genomic Revolution ETF pays none, and Canadian National Railway Co. is trading nearer its 52-week high, ARK Genomic Revolution ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | CNI | |
|---|---|---|
Sector | Sector/Thematic | Industrials |
52-Week High | $43.57 | $124.40 |
52-Week Low | $23.09 | $90.91 |
Market Cap | — | $75.28B |
Enterprise Value | — | $90.74B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
CNI trades at $124.40, up 0.05% with a bullish technical outlook. The company reported Q1 2026 EPS of $1.31, meeting expectations, and maintains strong profitability with a 27.23% net margin. Recent news highlights record propane shipments and a new potash transport agreement with BHP, signaling operational strength. Analyst consensus is a Buy with a $143.71 price target, implying 15.5% upside from current levels.
The stock presents a solid long-term opportunity driven by operational efficiency and strategic growth initiatives, though elevated valuation multiples and rising debt levels warrant caution. Near-term performance hinges on Q2 2026 earnings due July 24, 2026, with market sentiment leaning positive amid sustainable dividend payments and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Canadian National Railway Co.
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2019, CN delivered almost 6 million carloads over its 19,600 miles of track. CN generated roughly CAD 14 billion in total revenue by hauling intermodal containers (25% of consolidated revenue), petroleum and chemicals (21%), grain and fertilizers (16%), forest products (12%), metals and mining (11%), automotive shipments (6%), and coal (4%). Other items constitute the remaining revenue.
Read more on CNI →
